Pro Nephro AKI (NGAL) is now FDA-Cleared     READ MORE

Financials

Summary of Key Figures

More detailed information and explanations can be found in our Interim reports and Annual Report.

(1,000 DKK)20232022202120202019
Revenue30,95828,96924,25423,20426,622
Operating profit/loss before interest and tax (EBIT)(61,172)81,527(65,255)(63,590)(74,299)
Operating profit/loss before tax(61,207)(81,547)(63,840)(66,834)(74,247)
Net Loss(56,328)(75,923)(57,113)(61,562)(69,642)